Other substances

SARS-CoV-2 HRC lipopeptide

A SARS-CoV-2 spike protein derived lipoprotein.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

SARS-CoV-2 HRC lipopeptide represents a HRC domain of the SARS-CoV-2 spike protein conjugated (via 6 amino acid and tetra-ethylene glycol segment) to cholesterol (Outlaw et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain
Spike protein Peptide In vitro 		Vero E6 cells; human airway epithelia ex vivo 6.78

SARS-CoV-2 HRC lipopeptide inhibits spike protein mediated fusion in vitro, blocks the infection by life virus in cell culture (at IC50 ca. 6 nM) and inhibits the spread of infection in human airway epithelia ex vivo.

 Oct/20/2020
Export (.csv)